Emergent BioSolutions Posts Positive 2-Yr Persistence Data From CHIKV VLP Phase 2 Study
Emergent BioSolutions Inc. (EBS) announced Wednesday positive two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of investigational chikungunya virus virus-like particle or CHIKV VLP vaccine candidate in 415 healthy adults. Chikungunya virus is spread to people by infected mosquitoes and the symptoms include fever, joint pain, headache, muscle pain, joint swelling or rash. CHIKV […]
Read more